Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study

Intellia Therapeutics, Inc. (NTLA) announced that it has dosed the first patient in the phase III MAGNITUDE study evaluating its investigational in vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis, a rare and fatal disease that can lead to heart failure.The double-blind and placebo-controlled MAGNITUDE study will evaluate the safety and efficacy of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy.The company started dosing in the phase III MAGNIT ...